D09.22 — Carcinoma in situ of left eye
Is D09.22 billable?
Yes — D09.22 is billable for FY2027. D09.22 is a valid, billable ICD-10-CM code at the highest level of specificity in its branch. D09.22 may be submitted for encounters from October 1, 2026 through September 30, 2027.
D09.22 at a glance
| Code | D09.22 |
|---|---|
| Description | Carcinoma in situ of left eye |
| Billable | Yes |
| Code set | ICD-10-CM FY2027 |
| Valid for encounters | October 1, 2026 – September 30, 2027 |
Which MS-DRGs does D09.22 group to?
D09.22 sits in MDC 02 and helps define the logic of 2 MS-DRGs (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.
- 124Other Disorders of the Eye with MCC or Thrombolytic Agentmedical
- 125Other Disorders of the Eye without MCCmedical
Excludes1 — never code together — inherited from D09
The conditions below can never be reported together with D09.22 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.
- melanoma in situ (D03.-)
Excludes1 — never code together — inherited from D09.2
The conditions below can never be reported together with D09.22 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.
- carcinoma in situ of skin of eyelid (D04.1-)
How long has D09.22 existed?
D09.22 has been in ICD-10-CM since at least FY2016, the earliest fiscal year on record here.
Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.